BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced preclinical data with dacetuzumab describing a diagnostic gene signature that may identify lymphoma patients who are more likely to respond to dacetuzumab therapy. In addition, data demonstrating the enhanced activity of dacetuzumab in combination with conventional chemotherapy agents were reported. The data were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO.
